GSK to infuse £200M into UK manufacturing, pharma API In a strategic move to fortify its manufacturing capabilities, GlaxoSmithKline (GSK) is demonstrating a steadfast commitment to the United Kingdom, announcing an investment exceeding £200 million ($253 million) by 2025. The pharmaceutical giant is channeling substantial resources into enhancing its U.K. supply network, encompassing the construction of new facilities and the development of innovative assembly lines. A pivotal aspect of this initiative is the ongoing £67 million ($85 million) upgrade to GSK's manufacturing site in Montrose, Scotland. Scheduled for completion this year, the upgraded facility will play a crucial role in producing active pharmaceutical ingredients (API) to support the future supply of medicines. Furthermore, GSK is set to commence operations at its £65 million ($82 million) site in Ware, England, which commenced operations in September. This global manufacturing hub for GSK will be pivotal in manufacturing some of the company's most "commercially important" medicines, including those addressing HIV. GSK's commitment to the U.K. is underscored by its investment in six manufacturing sites across the country. This strategic move stands in contrast to some industry peers, such as AstraZeneca, which opted for international expansion, citing concerns about the U.K.'s tax policies. Notably, GSK is not limiting its investments to the U.K., recently pledging 250 million euros ($273 million) for a state-of-the-art facility at its Wavre campus in Belgium, supporting the company's burgeoning vaccine ambitions, including the launch of its RSV shot, Arexvy. As GSK forges ahead with these strategic investments, it solidifies its position as a key player in the global pharmaceutical landscape. #api #pharmamanufacturing #biotech #bigpharma #sanofi #gsk #pfizer #sunpharma #cipla #lupin #drreddys #pharmamarketing #pharmacompanies
Octanex Labs Pvt. Ltd.’s Post
More Relevant Posts
-
📢 We want to identify top companies with ready-for-market products in the biopharmaceutical industry and look for experts to conduct that analysis
🔔 #CallforProposals 83470023, closing 20 September 2024: To conduct the landscape assessment of the Biopharmaceutical Industry in South Africa The SAVax - "Vaccines for Africa - Rollout and Production in South Africa (SAVax)" project seeks a contractor to conduct a landscape assessment of South Africa's biopharmaceutical industry. South African companies face challenges in market intelligence, demand forecasting, high production costs, and complex technology transfers. These obstacles hinder their ability to establish local manufacturing capacities for vaccines, medicines, and health technologies. The assessment will identify companies with "ready-for-market" products that could potentially benefit from targeted technical assistance to enhance their manufacturing capacity and better meet market opportunities at national, regional, and continental levels. GIZ invites eligible and professional companies with local presence in South Africa, to participate in this tender. 📑Tender Documents are available for downloading here https://lnkd.in/da9FZqKy Completed forms must be submitted to [email protected]. Please quote reference 83470023 when submitting the documentation. Late submissions will not be accepted. 🔍 The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) SAVax project on behalf of the German Federal Ministry for Economic Cooperation and Development (BMZ) and the European Union, together with the Department of Science and Innovation (DSI) and National Department of Health (DoH), launches a tender to conduct a landscape assessment of the Biopharmaceutical Industry in South Africa. The SAVax - "Vaccines for Africa - Rollout and Production in South Africa (SAVax)" project aims to provide improved access to high-quality vaccines for all people living in South Africa. It has two components: supporting vaccine roll-out and boosting local vaccine production in South Africa for the African continent. Specifically, the project aims to enhance the enabling environment for local pharmaceutical and health technology production through research, development, and skills training, to strengthen the regulatory framework, and to support the demand and supply of locally produced health goods. This initiative is part of the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (TEI MAV+). #BiopharmaceuticalIndustryAssessment #VaccineProduction #LocalManufacturing #HealthInnovation #BiopharmaLandscape #SAHealthcare
-
-
60k | TMS | Neuroscience | Healthcare | Neuromodulation | Biotech | Business Development at Magstim
💊 Top Pharma Companies by Pipeline 💊 The pharmaceutical industry is set for a dynamic shift by 2024, with several leading companies gearing up to bring a significant number of drug candidates to the market. According to Citeline and company annual reports, here's a snapshot of the top pharmaceutical companies based on the size of their drug development pipelines. Leading the Pack 🐺 Roche (Switzerland): Dominating the field with an impressive 218 drug candidates, Roche is poised to lead the charge in pharmaceutical innovation. Pfizer (USA): Close behind, Pfizer has a robust pipeline of 205 candidates, reflecting its continued commitment to expanding therapeutic options. AstraZeneca (UK): With 166 drug candidates, AstraZeneca stands out as a major player in the race to develop new treatments. Strong Contenders 💪 Eli Lilly and Company (USA): Maintaining a strong presence with 159 candidates, Lilly is heavily invested in broadening its pharmaceutical offerings. Bristol Myers Squibb (USA): With 158 candidates, BMS remains a formidable force in drug development. Novartis (Switzerland): Continuing its legacy of innovation, Novartis has 154 candidates in its pipeline. Noteworthy Mentions 📰 Johnson & Johnson (USA): At 150 candidates, J&J is steadfast in its mission to advance global health. Hengrui Pharma Co.,Ltd (China): Representing China, Hengrui has a noteworthy pipeline with 147 candidates, showcasing the country's growing influence in the pharmaceutical sector. Merck (USA): With 145 candidates, Merck continues to be a key player in drug development. Sanofi (France): Sanofi’s pipeline of 142 candidates underlines its significant role in the industry. Emerging Competitors 🏋♂️ GSK (UK): GSK’s pipeline includes 138 candidates, reinforcing its competitive edge in the market. Takeda (Japan): With 130 candidates, Takeda highlights Japan’s contributions to pharmaceutical advancements. AbbVie (USA): Rounding out the list with 111 candidates, Abbvie remains a crucial participant in the pharmaceutical landscape. Credit Nicolas Schmitz for the great image and work getting this information together! #Pharma #Biotech #Healthcare #Medicine
-
-
As investors in the biotech and healthcare sectors, we're keeping a close eye on the companies with the most promising drug pipelines. These industry leaders are paving the way for new treatments and therapies, offering significant potential for growth and innovation. #PharmaceuticalIndustry #DrugDevelopment #Biotech #Investment
60k | TMS | Neuroscience | Healthcare | Neuromodulation | Biotech | Business Development at Magstim
💊 Top Pharma Companies by Pipeline 💊 The pharmaceutical industry is set for a dynamic shift by 2024, with several leading companies gearing up to bring a significant number of drug candidates to the market. According to Citeline and company annual reports, here's a snapshot of the top pharmaceutical companies based on the size of their drug development pipelines. Leading the Pack 🐺 Roche (Switzerland): Dominating the field with an impressive 218 drug candidates, Roche is poised to lead the charge in pharmaceutical innovation. Pfizer (USA): Close behind, Pfizer has a robust pipeline of 205 candidates, reflecting its continued commitment to expanding therapeutic options. AstraZeneca (UK): With 166 drug candidates, AstraZeneca stands out as a major player in the race to develop new treatments. Strong Contenders 💪 Eli Lilly and Company (USA): Maintaining a strong presence with 159 candidates, Lilly is heavily invested in broadening its pharmaceutical offerings. Bristol Myers Squibb (USA): With 158 candidates, BMS remains a formidable force in drug development. Novartis (Switzerland): Continuing its legacy of innovation, Novartis has 154 candidates in its pipeline. Noteworthy Mentions 📰 Johnson & Johnson (USA): At 150 candidates, J&J is steadfast in its mission to advance global health. Hengrui Pharma Co.,Ltd (China): Representing China, Hengrui has a noteworthy pipeline with 147 candidates, showcasing the country's growing influence in the pharmaceutical sector. Merck (USA): With 145 candidates, Merck continues to be a key player in drug development. Sanofi (France): Sanofi’s pipeline of 142 candidates underlines its significant role in the industry. Emerging Competitors 🏋♂️ GSK (UK): GSK’s pipeline includes 138 candidates, reinforcing its competitive edge in the market. Takeda (Japan): With 130 candidates, Takeda highlights Japan’s contributions to pharmaceutical advancements. AbbVie (USA): Rounding out the list with 111 candidates, Abbvie remains a crucial participant in the pharmaceutical landscape. Credit Nicolas Schmitz for the great image and work getting this information together! #Pharma #Biotech #Healthcare #Medicine
-
-
Medicinal Chemistry - Project Leader; Technology Innovation & External Platforms presso Alfasigma - parla di #scienze #farmaci #farmaceutico #ricerca #innovazione #sociale
PHARMACEUTICAL INDUSTRY: WORKING IN PROGRESS... What should we expect from the pharmaceutical industry by 2024? Here's a snapshot of the top pharmaceutical companies based on the size of their drug development pipelines, according to Citeline and company annual reports. #pharma #drug #drugpipeline
60k | TMS | Neuroscience | Healthcare | Neuromodulation | Biotech | Business Development at Magstim
💊 Top Pharma Companies by Pipeline 💊 The pharmaceutical industry is set for a dynamic shift by 2024, with several leading companies gearing up to bring a significant number of drug candidates to the market. According to Citeline and company annual reports, here's a snapshot of the top pharmaceutical companies based on the size of their drug development pipelines. Leading the Pack 🐺 Roche (Switzerland): Dominating the field with an impressive 218 drug candidates, Roche is poised to lead the charge in pharmaceutical innovation. Pfizer (USA): Close behind, Pfizer has a robust pipeline of 205 candidates, reflecting its continued commitment to expanding therapeutic options. AstraZeneca (UK): With 166 drug candidates, AstraZeneca stands out as a major player in the race to develop new treatments. Strong Contenders 💪 Eli Lilly and Company (USA): Maintaining a strong presence with 159 candidates, Lilly is heavily invested in broadening its pharmaceutical offerings. Bristol Myers Squibb (USA): With 158 candidates, BMS remains a formidable force in drug development. Novartis (Switzerland): Continuing its legacy of innovation, Novartis has 154 candidates in its pipeline. Noteworthy Mentions 📰 Johnson & Johnson (USA): At 150 candidates, J&J is steadfast in its mission to advance global health. Hengrui Pharma Co.,Ltd (China): Representing China, Hengrui has a noteworthy pipeline with 147 candidates, showcasing the country's growing influence in the pharmaceutical sector. Merck (USA): With 145 candidates, Merck continues to be a key player in drug development. Sanofi (France): Sanofi’s pipeline of 142 candidates underlines its significant role in the industry. Emerging Competitors 🏋♂️ GSK (UK): GSK’s pipeline includes 138 candidates, reinforcing its competitive edge in the market. Takeda (Japan): With 130 candidates, Takeda highlights Japan’s contributions to pharmaceutical advancements. AbbVie (USA): Rounding out the list with 111 candidates, Abbvie remains a crucial participant in the pharmaceutical landscape. Credit Nicolas Schmitz for the great image and work getting this information together! #Pharma #Biotech #Healthcare #Medicine
-
-
Mankind Pharma Acquires Bharat Serums and Vaccines Limited for Rs 13,630 Crore In a significant move within the pharmaceutical industry, Mankind Pharma has acquired Bharat Serums and Vaccines Limited for a whopping Rs 13,630 crore. This strategic acquisition is set to bolster Mankind Pharma's portfolio, enhancing its capabilities in the biotech and vaccine sectors, and positioning it as a stronger player in the global market. Our latest blog post, "Mankind Pharma Acquires Bharat Serums and Vaccines Limited for Rs 13,630 Crore," explores the details of this landmark deal, the strategic benefits for Mankind Pharma, and the anticipated impact on the healthcare industry. https://lnkd.in/ebyYwfHa #MankindPharma #BharatSerumsAndVaccines #Pharmaceuticals #Biotech #Healthcare #StrategicAcquisition #IndustryNews #GlobalHealthcare #InnovationInHealth #PharmaGrowth #youtubeshorts #shorts #facebook #linkedln What do you think about this major acquisition in the pharma industry? Share your insights and perspectives in the comments below! If you found this update valuable, like and share this post to keep your network informed.
-
Zuellig Pharma Group CEO John A. Graham speaks to BioPharma APAC, sharing details about our strategic partnership with SUBSTIPHARM Biologics, which aims to revolutionise the healthcare landscape in Asia. The expansion of the commercialisation agreement, with a focus on innovative vaccines, reflects a joint commitment to delivering life-saving products to communities in need. In the interview, John discussed the decision-making process, regulatory navigation, and the pivotal role the partnership plays in addressing significant health concerns like Japanese Encephalitis. Additionally, he provided insights on how Zuellig Pharma, through ZP Therapeutics, plans to leverage our extensive and proven in-market expertise in warehousing and distribution (W&D), industry-leading cold chain management, as well as standards of excellence in ethics and compliance to support Substipharm Biologics in marketing and distributing innovative vaccines across diverse markets in Asia. Read the full interview here: https://lnkd.in/gaujEeax #ZuelligPharma #ZPTherapeutics #MakingHealthcareMoreAccessible #Vaccines #ColdChainManagement
-
𝐂𝐑𝐎 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 - 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐛𝐞 𝐭𝐡𝐞 𝐋𝐚𝐫𝐠𝐞𝐬𝐭 𝐑𝐞𝐠𝐢𝐨𝐧 𝐅𝐨𝐥𝐥𝐨𝐰𝐞𝐝 𝐁𝐲 𝐄𝐮𝐫𝐨𝐩𝐞 𝐭𝐨 𝐛𝐞 𝐒𝐞𝐜𝐨𝐧𝐝-𝐋𝐚𝐫𝐠𝐞𝐬𝐭 --> Download PDF Brochure to Know More@ https://lnkd.in/dkKQGHza Geographically, the CRO Services market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. 𝘛𝘩𝘦 𝘮𝘢𝘳𝘬𝘦𝘵 𝘸𝘢𝘴 𝘥𝘰𝘮𝘪𝘯𝘢𝘵𝘦𝘥 𝘣𝘺 𝘕𝘰𝘳𝘵𝘩 𝘈𝘮𝘦𝘳𝘪𝘤𝘢 𝘪𝘯 2023 𝘢𝘯𝘥 𝘵𝘩𝘪𝘴 𝘥𝘰𝘮𝘪𝘯𝘢𝘯𝘤𝘦 𝘪𝘴 𝘢𝘯𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦𝘥 𝘵𝘰 𝘤𝘰𝘯𝘵𝘪𝘯𝘶𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘰𝘶𝘵 𝘵𝘩𝘦 𝘧𝘰𝘳𝘦𝘤𝘢𝘴𝘵 𝘱𝘦𝘳𝘪𝘰𝘥 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 2024 𝘢𝘯𝘥 2029. 𝑻𝒉𝒆 𝑬𝒖𝒓𝒐𝒑𝒆𝒂𝒏 𝒎𝒂𝒓𝒌𝒆𝒕 𝒊𝒔 𝒕𝒉𝒆 𝒔𝒆𝒄𝒐𝒏𝒅-𝒍𝒂𝒓𝒈𝒆𝒔𝒕 𝑪𝑹𝑶 𝑺𝒆𝒓𝒗𝒊𝒄𝒆𝒔 𝒎𝒂𝒓𝒌𝒆𝒕 𝒈𝒍𝒐𝒃𝒂𝒍𝒍𝒚, mainly due to factors such as growing investment in the pharmaceutical and biotechnology R&D along with presence of players involved in pharmaceutical drug development. Moreover, growing number of clinical trials in the region is another factor supporting the growth of European CRO Services market. Key Players of This Market: IQVIA Labcorp Thermo Fisher Scientific ICON plc WuXi AppTec Syneos Health Charles River Laboratories Pharmaron Fortrea Eurofins Medpace among others. --> Recent Developments: In October 2023, IQVIA Inc. (US) and argenx (US) entered a strategic collaboration to support treatment for patients suffering from rare autoimmune disorders through innovative and comprehensive technology-enabled pharmacovigilance (PV) safety services and solutions. In October 2023, Labcorp announced the acquisition of the outreach laboratory business and selected operating assets of Baystate Health, comprising laboratory service centres operated by Baystate Health throughout Massachusetts, US.
-
Mark Cuban's drug company partners with 1st health system On March 7, Franklin, Tenn.-based Community Health Systems became the first hospital system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co. CHS is partnering with Mark Cuban's pharmaceutical company, which sells thousands of drugs at a discounted rate, to address drug supply issues. The two organizations said they will focus on the rising cost of pharmaceuticals, drug shortages, pharmaceutical waste, and patient safety and medication error prevention, according to a CHS news release. Mr. Cuban's company offers "more flexible ordering opportunities, including alternative vial sizes for drug administration, which can reduce waste," the release said. "Because Cost Plus Drugs will provide drugs in vial sizes that many other drug manufacturers won't offer, there is less potential for dosage errors when drugs must be measured prior to administration at the bedside." https://buff.ly/3TtD4eG
